ANNOUNCEMENT 15 Jun 2020

On 15 June 2020, the UK authorities announced imposing an export ban on two pharmaceutical forms of dexamethasone (oral solution and solution for injection) following the drug has proven to reduce the risk of death significantly in COVID-19 patients.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

The UK Government, “Medicines that cannot be parallel exported from the UK”, Available at: https://www.gov.uk/government/publications/medicines-that-cannot-be-parallel-exported-from-the-uk#history

The UK Government, List of medicines that cannot be parallel exported from the UK, last updated 15 June 2020. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/892354/Medicines_that_cannot_be_parallel_exported_from_the_UK_15_June_2020.csv/preview

Inception date: 15 Jun 2020 | Removal date: open ended

Export ban

On 15 June 2020, the Department of Health and Social Care of the United Kingdom added two pharmaceutical forms of dexamethasone (oral solution and solution for injection) to the list of medicines that cannot be parallel exported from the UK. The decision is taken after an Oxford University study has proven the drug to reduce the risk of death significantly in COVID-19 patients.

The UK authorities noted that: “Parallel export of a medicine on the list is considered a breach of regulation 43(2) of the Human Medicines Regulations 2012 and a contravention of the wholesale dealer license and may lead to regulatory action by the Medicines and Healthcare products Regulatory Agency (MHRA), which could include immediate suspension of the wholesale dealer license.”

Previously, on 23 April 2020, the parallel export of 33 medicines was banned (see related state act). 

AFFECTED SECTORS

 

AFFECTED PRODUCTS